Search research articles
Contact Us
Filters
Showing results (231-240 of 272) with videos related to
Page
of 28
Sort By:
Breast (Edinburgh, Scotland)
|
July 26, 2024
Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study
Caterina Caminiti, Giuseppe Maglietta, Laura Arenare, et al.
The Lancet. Oncology
|
July 13, 2016
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study
Marina Bagnoli, Silvana Canevari, Daniela Califano, et al.
Cancer Research Communications
|
December 19, 2025
CCDC6 immunostaining in conjunction with the Rad51 HRD assay may expand PARPi treatment eligibility in HGSOC patients
Daniela Criscuolo, Francesco Merolla, Benedetta Pellegrino, et al.
BMC Public Health
|
April 10, 2026
Cancer in migrant populations: evidence from a regional oncology network
Elisabetta Coppola, Chiara D'Alessio, Gabriele Calvanese, et al.
BMJ Open
|
October 21, 2021
Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system
Silvia Riva, Laura Arenare, Massimo Di Maio, et al.
The Lancet. Oncology
|
December 3, 2014
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial
Peter M Ellis, Frances A Shepherd, Michael Millward, et al.
Journal of Endocrinological Investigation
|
April 23, 2025
Vaccination of people with solid tumors and diabetes: existing evidence and recommendations. A position statement from a multidisciplinary panel of scientific societies
Marco Gallo, Angioletta Lasagna, Valerio Renzelli, et al.
Therapeutic Advances in Medical Oncology
|
August 28, 2020
Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with <i>RAS</i>-mutated metastatic colorectal cancer: the REVOLUTION study protocol
Antonio Avallone, Maria Carmela Piccirillo, Elena Di Gennaro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2018
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials
Cesare Gridelli, Alessandro Morabito, Luigi Cavanna, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials
Alessandro Morabito, Maria Carmela Piccirillo, Paolo Maione, et al.
Page
of 28
Search research articles
Search
Showing results (231-240 of 272) with videos related to
Sort By:
Page
of 28
Breast (Edinburgh, Scotland)
|
July 26, 2024
Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study
Caterina Caminiti, Giuseppe Maglietta, Laura Arenare, et al.
The Lancet. Oncology
|
July 13, 2016
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study
Marina Bagnoli, Silvana Canevari, Daniela Califano, et al.
Cancer Research Communications
|
December 19, 2025
CCDC6 immunostaining in conjunction with the Rad51 HRD assay may expand PARPi treatment eligibility in HGSOC patients
Daniela Criscuolo, Francesco Merolla, Benedetta Pellegrino, et al.
BMC Public Health
|
April 10, 2026
Cancer in migrant populations: evidence from a regional oncology network
Elisabetta Coppola, Chiara D'Alessio, Gabriele Calvanese, et al.
BMJ Open
|
October 21, 2021
Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system
Silvia Riva, Laura Arenare, Massimo Di Maio, et al.
The Lancet. Oncology
|
December 3, 2014
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial
Peter M Ellis, Frances A Shepherd, Michael Millward, et al.
Journal of Endocrinological Investigation
|
April 23, 2025
Vaccination of people with solid tumors and diabetes: existing evidence and recommendations. A position statement from a multidisciplinary panel of scientific societies
Marco Gallo, Angioletta Lasagna, Valerio Renzelli, et al.
Therapeutic Advances in Medical Oncology
|
August 28, 2020
Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with <i>RAS</i>-mutated metastatic colorectal cancer: the REVOLUTION study protocol
Antonio Avallone, Maria Carmela Piccirillo, Elena Di Gennaro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2018
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials
Cesare Gridelli, Alessandro Morabito, Luigi Cavanna, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials
Alessandro Morabito, Maria Carmela Piccirillo, Paolo Maione, et al.
Page
of 28